| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8776794 | The Breast | 2018 | 7 Pages |
Abstract
OS, duration of trastuzumab, and frequency of cardiac monitoring increased over the study period. Outcomes for trastuzumab in this heterogeneous real world population were reassuringly comparable to those from clinical trials, with the median OSÂ >Â 3 years in Group Two and 25% of patients living 7 years or longer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Benjamin Daniels, Belinda E. Kiely, Sarah J. Lord, Nehmat Houssami, Christine Y. Lu, Robyn L. Ward, Sallie-Anne Pearson,